Design Therapeutics Inc
NASDAQ:DSGN
Design Therapeutics Inc
Other Equity
Design Therapeutics Inc
Other Equity Peer Comparison
Competitive Other Equity Analysis
Latest Figures & CAGR of Competitors
Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Design Therapeutics Inc
NASDAQ:DSGN
|
Other Equity
$62k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$69m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
-$190m
|
CAGR 3-Years
39%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
$27.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
-$77.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Design Therapeutics Inc's Other Equity?
Other Equity
62k
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Other Equity amounts to 62k USD.
What is Design Therapeutics Inc's Other Equity growth rate?
Other Equity CAGR 3Y
-32%
The average annual Other Equity growth rates for Design Therapeutics Inc have been -32% over the past three years .